0001437749-21-026281.txt : 20211112 0001437749-21-026281.hdr.sgml : 20211112 20211112073020 ACCESSION NUMBER: 0001437749-21-026281 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20211112 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474671999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 211399577 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 8-K 1 mbrx20211106_8k.htm FORM 8-K mbrx20211106_8k.htm
false 0001659617 0001659617 2021-11-12 2021-11-12
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 12, 2021
 
moleculinlogoresizedclear.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
delaware
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
 
5300 Memorial Drive, Suite 950, Houston, TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
 
 
 
Item 2.02     Results of Operations and Financial Condition.
 
On November 11, 2021, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01      Financial Statements and Exhibits.
 
(d)     Exhibits.
 
Exhibit No.
 Description
 
99.1
 
104
   Cover page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC.
   
   
 
Date: November 12, 2021
   
 
By: /s/ Jonathan P. Foster
 
Jonathan P. Foster
Chief Financial Officer
 
2
 EX-99.1 2 ex_303877.htm EXHIBIT 99.1 ex_303877.htm

Exhibit 99.1

ex_303877img001.jpg

 

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update

 

– Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 –

 

– Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (STS) lung metastases –

 

–STS lung metastases trial continues to recruit rapidly –

 

– Received favorable opinion from the MHRA to commence first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, expected to commence in Q4 2021 –

 

– Additional key clinical and regulatory milestones expected throughout the next 18 months –

 

HOUSTON, November 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin, we or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.

 

“With up to six clinical trials that are either currently underway or expected to have regulatory clearance by the end of 2021, we have made tremendous fundamental progress, and this is truly an exciting time at Moleculin. Furthermore, we believe at least one additional trial will be approved in early 2022. We continue to be encouraged by both the demonstrated potential and data seen across our portfolio of drug candidates,” commented Walter Klemp, Chairman and CEO of Moleculin.

 

He continued “We are extremely pleased that the STS lung metastases trial recently expanded to a total of three sites and that we are now in the third cohort with the first patient already treated and the final two patients in screening. This trial continues to recruit rapidly, and, on this pace, we could see the Phase 2 begin in the first half of 2022.”

 

Concluding, he added “The unmet medical needs that people with highly resistant tumors and viruses are faced with continue to be a driving force as we work to develop safe and effective treatments in a number of oncology and viral indications. We are dedicated to advancing our three core technologies and, I believe, are well-positioned to achieve the key value drivers we expect to see over the next 18 months.”

 

 

Recent Highlights

 

 

●

Received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19. The Company also announced it has received a favorable opinion from the London - Riverside Research Ethics Committee in the UK to begin the study, which is expected to be conducted at the Medicines Evaluation Unit in Manchester, United Kingdom.
 

●

Reported interim results from its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which documented preliminary clinical activity for Annamycin.

 

Programs Update

 

Next Generation Anthracycline - Annamycin

 

Annamycin, the Company’s next-generation anthracycline was designed to be noncardiotoxic (unlike all currently approved anthracyclines) and has demonstrated its lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML. The Company believes that, because of this unique improvement in safety, the use of Annamycin may not face the same usage limitations imposed on doxorubicin and other currently approved anthracyclines. Additionally, Annamycin has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Annamycin is currently in development for the treatment of AML and STS lung metastases. For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.

 

 
 

 

Upcoming Milestones Expectations

 

 

●

H2 2021: Report cohort topline results from the ongoing Phase 1/2 study for treatment of AML and report the study's topline results.
 

●

H2 2021: Report cohort topline results from the ongoing Phase 1/2 study for treatment of STS lung metastases and report the study's topline results.
 

●

H2 2021: Initiate Phase 1/2 study in Europe for the treatment of AML evaluating combination therapy of Annamycin + Ara-C.
 

●

H1 2022: Commencement of an investigator-funded, second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases in Europe.
 

●

H1 2022: Complete Phase 1b portion of ongoing Phase 1b/2 study of Annamycin for the treatment of sarcoma lung metastases in the US.

 

First-in-class p-STAT3 inhibitors - WP1066 and WP1220

 

WP1066 is one of several Immune/Transcription Modulators, designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3 (phosphorylated signal transducer and activator of transcription 3), c-Myc (a cellular signal transducer named after a homologous avian virus called Myelocytomatosis) and HIF-1α (hypoxia inducible factor 1α). These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation, and the angiogenesis (coopting vasculature for blood supply), invasion, metastasis and inflammation associated with tumors. They may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors. WP1220 is a close analog to WP1066 that the Company has developed as a potential topical therapy for skin-related diseases.

 

WP1220 was evaluated for the treatment of Cutaneous T-Cell Lymphoma (CTCL) and, based on those results, we are seeking collaborators for future development. WP1066 is currently being evaluated for the treatment of pediatric brain tumors, including Diffuse Interstitial Pontine Glioma (DIPG). Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme (GBM).

 

Upcoming Milestones Expectations

 

 

●

H2 2021: File a US Investigational New Drug application (IND) for the treatment of certain adult cancer(s) with WP1066 and begin to identify an institution to commence an associated investigator-funded Phase 1a/1b study.
 

●

H1 2022: Report topline results from Phase 1 physician-sponsored pediatric brain tumor clinical trial.
 

●

H2 2022: Facilitate launch of physician-sponsored Phase 2 study of WP1066 for the treatment of pediatric brain tumors including DIPG.
 

●

Actively seek collaboration with a strategic partner in the near term for external funding for the continued development of WP1220 in a Phase 2 clinical trial as a topical therapy for CTCL.

 

Infectious Disease and Metabolism/Glycosylation Inhibitors- WP1122, WP1096 and WP1097 Portfolio

 

Moleculin has new compounds designed to target the roles of glycolysis and glycosylation in both cancer and viral diseases. The Company’s lead Metabolism/Glycosylation Inhibitor, WP1122, is a prodrug of 2-DG that appears to improve the drug-like properties of 2-DG by increasing its circulation time and improving tissue/organ distribution. Based on recently published research that has identified that 2-DG has antiviral potential against SARS-CoV-2 in vitro, Moleculin believes WP1122 has significant potential as a COVID-19 therapy.  Its unique mechanism of action may also be well-suited for combinations that potentiate existing therapies, including checkpoint inhibitors.

 

The Company recently received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a Phase 1a clinical trial of WP1122 in the United Kingdom. The Company also received a favorable opinion from the London - Riverside Research Ethics Committee in the UK to begin the study, which is expected to be conducted at the Medicines Evaluation Unit in Manchester, United Kingdom. The Phase 1a study in healthy human volunteers will investigate the effects of a single ascending dose (SAD) and multiple days of ascending dosing (MAD) of WP1122 administered as an oral solution. Dose escalation will take place in sequential SAD cohorts, and MAD will start as soon as SAD has completed at least 3 dosing cohorts in which WP1122 is found to be safe and well-tolerated. This study in healthy volunteers will explore safety and pharmacokinetics (PK), and subsequent clinical development will be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. The Company expects to enroll approximately 80 healthy volunteers in the United Kingdom.

 

Additionally, the Company is in the process of identifying countries where potential future Phase 2 clinical studies could occur. The Company is also engaged in preclinical development of additional antimetabolites (WP1096 and WP1097) targeting glucose and mannose metabolism.

 

 

 
 

 

Upcoming Milestones Expectations

 

 

●

H2 2021: Commence Phase 1a study of WP1122 for the treatment of COVID-19 in the UK.
 

●

H2 2021: File an IND in the US for the treatment of certain cancers such as GBM and pancreatic cancer with WP1122.
 

●

H1 2022: Potential to launch Phase 2 pivotal study of WP1122 for the treatment of COVID-19 outside of the US.
 

●

Ongoing preclinical development work in anti-viral indications such as HIV, Zika, and Dengue. Collaborations targeted for 2022.

 

Summary of Financial Results for Third Quarter 2021

 

Research and development (R&D) expense was $4.1 million and $4.4 million for the three months ended September 30, 2021 and 2020, respectively. The decrease of $0.3 million is mainly related to the timing of costs incurred in 2020 of producing additional drug product for Annamycin clinical trials.

 

General and administrative expense was $2.0 million and $1.7 million for the three months ended September 30, 2021 and 2020, respectively. The increase of $0.3 million is mainly related to an increase in consulting and advisory fees and an increase in our corporate insurance.

 

For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of $13.1 million and $14.7 million, respectively, and had net cash flows used in operating activities of $14.7 million and $14.6 million, respectively.

 

The Company ended the quarter with $75.2 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&D rate of expenditures, into 2024.

 

About Moleculin Biotech, Inc.

 

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to be noncardiotoxic and to avoid multidrug resistance mechanisms. In addition, Annamycin has been shown in animal models to reach higher concentration levels than doxorubicin (a leading anthracycline) in certain key organs, such as the lungs, liver and pancreas considered to be difficult-to-reach "sanctuary sites" for tumors. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

 

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

 

 
 

 

Forward-Looking Statements

 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company’ ability to have up to six clinical trials either underway or to have regulatory clearance by the end of 2021, and to have an additional trial approved in early 2022; the Company’s ability to meet the clinical trial milestones described in this release; whether the pre-clinical results for WP1122 described are able to be replicated in clinical trials; and the Company’s forecasted cash burn rate. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

 

JTC Team, LLC

Jenene Thomas

(833) 475-8247

MBRX@jtcir.com

 

 

-- Financial Tables Follow--

 

 

 
 

 

 

 

 

Moleculin Biotech, Inc.

                

Unaudited Condensed Consolidated Balance Sheets

                

(in thousands)

  

September 30, 2021

    

December 31, 2020

  

Current assets:

                

Cash and cash equivalents

  

$

75,178

    

$

15,173

  

Prepaid expenses and other current assets

    

1,892

      

2,025

  

Total current assets

    

77,070

      

17,198

  

Furniture and equipment, net

    

353

      

483

  

Intangible assets

    

11,148

      

11,148

  

Operating lease right-of-use asset

    

131

      

202

  

Total assets

  

$

88,702

    

$

29,031

  
                 

Current liabilities:

                

Accounts payable and accrued expenses and other current liabilities

  

$

3,656

    

$

2,920

  

Total current liabilities

    

3,656

      

2,920

  

Operating lease liability - long-term, net of current portion

    

75

      

159

  

Warrant liability - long term

    

3,712

      

8,192

  

Total liabilities

    

7,443

      

11,271

  

Total stockholders' equity

    

81,259

      

17,760

  

Total liabilities and stockholders' equity

  

$

88,702

    

$

29,031

  

 

 

Unaudited Condensed Consolidated Statements of Operations

                                
   

Three Months Ended September 30,

    

Nine Months Ended September, 30

  

(in thousands, except share and per share amounts)

  

2021

    

2020

    

2021

    

2020

  

Revenues

  

$

—

    

$

—

    

$

—

    

$

—

  

Operating expenses:

                                

Research and development

    

4,095

      

4,435

      

11,239

      

10,971

  

General and administrative and depreciation

    

2,062

      

1,716

      

6,524

      

5,276

  

Total operating expenses

    

6,157

      

6,151

      

17,763

      

16,247

  

Loss from operations

    

(6,157

)

    

(6,151

)

    

(17,763

)

    

(16,247

)

Other income:

                                

Gain from change in fair value of warrant liability

    

1,678

      

2,743

 

    

4,428

      

1,489

 

Other income, net

    

13

      

10

      

30

      

32

  

Interest income, net

    

87

      

3

      

236

      

10

  

Net loss

  

$

(4,379

)

  

$

(3,395

)

  

$

(13,069

)

  

$

(14,716

)

Net loss per common share - basic and diluted

  

$

(0.15

)

  

$

(0.33

)

  

$

(0.50

)

  

$

(1.55

)

Weighted average common shares outstanding - basic and diluted

    

28,573,476

      

10,245,810

      

26,302,638

      

9,496,585

  

 

 

 
 EX-101.SCH 3 mbrx-20211112.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 mbrx-20211112_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 mbrx-20211112_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Entity, Ex Transition Period Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 mbrx-20211112_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 ex_303877img001.jpg begin 644 ex_303877img001.jpg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moleculinlogoresizedclear.jpg begin 644 moleculinlogoresizedclear.jpg M_]C_X 02D9)1@ ! 0 2 !( #_X0"L17AI9@ 34T *@ @ !0$2 , M ! $ $: 4 ! 2@$; 4 ! 4@$Q ( @ 6H=I M 0 ! >@ !( 0 $@ !061O8F4@4&AO=&]S:&]P M($-3-2XQ($UA8VEN=&]S: Z ! , ! $ * " 0 ! XZ # M 0 ! / #_X0M":'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI. M5&-Z:V,Y9"(_/B \>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O M(B!X.GAM<'1K/2)835 @0V]R92 V+C N,"(^(#QR9&8Z4D1&('AM;&YS.G)D M9CTB:'1T<#HO+W=W=RYW,RYO7!E+U)E&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O M(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C(Q.4-#0C)#03DX,S$Q13(X M-S,X1#$T03#IX;7!M971A/B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_ M>'!A8VME="!E;F0](GH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? M 0 # 0$! 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$ M! ! G< 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(RKR\_3U]O?X^?K_VP!# $! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" M @,# P,# P,# P/_VP!# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_W0 $ !W_V@ , M P$ A$#$0 _ /[^* "@#XY_:H_;U_9?_8WL+=_C9\1[33O$NHVSW>A_#GPY M:S^*?B1KUNG'VJP\(Z5YE]::86!7[??&ST]&&&G%??\ !/ACQIX@591X;P%">"P M'(]+%?0]RUTG]1SO%1K6=O:82E*-^E^3$J27FHR?DSS*7TT,-&HO;Y11E!RB MFH8FK&5FUS-<^%46TKM*4H)M6Z_6/]EG_ (+0_L;?M+:II7A#4M>U?X&? M$/6+F&PTOPO\75TO3-'US4[B6*"VTWPW\0M)O]2\$ZGJ-Y-.J6]G/=V>H3L< M);D@BOPKC;Z//B%P;0GCX4:>9933BY3JX7FE*$4FW*I0G&->$8I-RG[.5-=9 MJZO^]<$_2!\.>-:T,%1Q,L%F52:A&GB>6$9S;@E&G7C*="1_G_.:_"GH?MPM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % '__T/[^* /B;]LOXD_M/:3X7MOAC^QO\-5\8?'/QS!/'%X^ M\4RV6C_"KX)^'L2Q3^-_%^M:N&M=8U^65&BT?1;.#4+F6<&YN+E'D34OQJ\$_\&^WBGXAZ MWJ_Q"_:\_:O\0^)O'/B^[BUGQ<+]%VKG^)JYOXB9S6Q.9XJG!U8X>$'^]2?-*5? M$1J.KRW4:;6'HJ"3Y81BU"/VKX=_X(.?\$^]$M8;?4O#7Q;\6RQHJO=Z[\:O M'-A),P W.UKX0OO#&G(6/9(E4>G3'YUBOI-^*V(J.=+$8&@F]H8+#R2^=6%2 M7WM_Y?HV"^CAX583#QP\L)BJJBK7GB\2F_\ P"I!:^21K:K_ ,$+/^"=^H0O M%9_#WXD:$[K@7&D_'+XJO+&3_$L6L>)M7M'(/.'C8?AUPH_26\6J'/#'Q'\-S(6#-87=UH5KX%\326LF,$S7-V!Q MN1P,']!R/Z7'$5"<(<1Y7A,326\\/4JX>I?^9*;K4D_\-./DUN?G.;_1(X2G MS5N&\PQ>$Q3J*25:-/$0:NGR2:C1K2C=:*5:5FE=22Y3WG]B9/V^/V$?$>C? ML]_M::'<_&S]F;5KY-"^&W[17@36]2^(#?![4KBZ%OHWA_XB6VI6=E\0-*^% MNKO+'#;W=[:WMOX6G94EU!M+8'3_ );Q&GX7>)>$J<5\#5%EG&%.//B,!6IQ MH+%Q4;SJ8>4)2H2Q,+-RA&5-XI*\**KJU;[#P[H^)GAU6APOQM&6:<*SJ..' MQ]*I.O4P\IU&H4\1"<57CAVG%1F_;+"_#4K/#I3I?N@#FOYL/Z$"@ H * "@ M H * "@ H * "@ H * "@ H * "@ H * "@ H * /__1_OXH ^7OBW^VM^R1 M\";HV'Q<_:*^$'@?5T#DZ#J_CC17\28CX?9X;T^YOM==E)Q@6^><#>')^RSW-,!A*SBVH5:].,V MENU!RYFM5LGNO(^0]1_X+:?\$WM/NYK2/XZZOJGDN8VNM$^#WQEU6P8^L5]: M^!7MYUP>J,0?6OOZ7T$V=P<\'GF"ARMIJNY89IIV=XXB-)K;=JW;2U_OGPGX MV\'>/='@\0>!_%?AOQCH-TJ/;:WX5US3/$.DSHZ[T:+4=)NKRT=67D?/7Y=C ML9)-'Z?A<9A,=16(P56G6P\E=2A)2BT^J<6T M_O?^?45QG0(0#U&>WX>G;@T[L Z#Z#I]/SI ?@G^V%_P7&TK]DO]I#XG?L]W M/[-^I>.)OAQ>>&K1_%<'Q2T[P]!JQ\1>"O#?C%771[GP?J4MF+1/$(@.9Y Y MB+Y ;:O]/^'_ -&O&<><(8+BNEF]+#0QD:C5)X:+V\0>'?%G]MVD6LP M7-MH6A)9FPUKP]<6TL.V4@&*0L/,"CXCQ<\&\=X4_4:E7&1QV&QOM8\\:3I< ME2ER-P:3P]\+O OB;QSJEM M%((I[Z#P[I5SJ*Z;:R%) MYJ<\*6\/RM^]E7@]#^8\-Y'B^)L_P7#V M]R3%Y[C;_5,'AZE::6[C3BY-+S=K+S:/ MYS)/^#E'2X+>8S?L>ZLMW;6DTUQ;)\;](D6.>VMWFN(!,/A_O=$>-E#[,L!G M;VK^MX_0]Q/B!\/? GCP6!TH>-O!OA?Q< M-+-R+TZ:/$FAV&M?8#>""V%T;/[;Y?F"-/,V[MJYP/X]S3!?V;F6(R[FYW0K MU*?-:W-R3E&]KNU[7MTO\W_8V"Q/US!T<7;E]K2C.V]N:*E:_6U['9UP'2-= MMJ,V,[59L>N!G'XXIK5V!Z*Y^)7[%_\ P61L_P!K[]IO3_V<8/V>[_P#)>Z9 M\1M1;QA2.S]OZ)\0O "OP#P8^ M,*F:T\5#GP\526'E3?[]-IN;J27NVV2=_+K^!< ^.V%X\XSJ\'T,MK8:=&.( M;JRK0G%O#SC!J,(QYM6[WDXVTY5--N/[;U_.I^^A0 4 % !0 4 (3@$^@)_* MFM78#\._B]_P6#KB[A_L4_$ VJW4GVC[,,2IYI\O^C\@^CW5SWPXCXA1S:%*G M++L5BG0>'E*2^K/$_N_:*JHOVGU?XFER\WPOE7-_/6?>/='(O$C_ (AU/*JE M2O+'8:A&NL1!0Y<0L->I*#I\Z=-XBW)%34K0?M(\T_9Y/[;'_!;;2/V-_P!H MSQU^S]>?L]W7CR?P5IWA/43XGA^*VD^&5U%?%/AJQ\0K$-%N_">I7%N]D+SR MCB:7S-H;"[@*Z/#CZ..,\0N$\-Q51S6&&AB*E6/LWAIU.7V9[:*\>;] MTK.X^UVEM=;/+^T6\$^S=NV>=$DNW=A<[=^,XYK^:9QY9N/9M'](1?-%2[HL MU(PH * /_]+^\'XE>!-'^*'P]\;?#?Q#?:YIV@>//"VN>$-;O?#.M7?ASQ!; MZ3XAT^?2]1?1O$&GLE_HNI&TN7$5U R30.0\;*X!'HY3F5?)\TP^;86-.>*P MU:%6"J0C4IN5.2E'GIR3C.-TKQDG&2TDFG9\F/P=+,,%5P%=SC0K4Y0DXR<9 M*,E9\LEK%V>C5FGJFGJ?FCH'_!$7_@FSX>B>.'X$:I?O(NV>?5?BW\7[A[@G MJ\RQ^-H+9Y"QSN" YK]CQ?TC_&'&-2J9K&*3TY<+A%;T_#N% MDYTLI;[IT,/Q+_P $+O\ @G?KMO+!IGP[^(7@N64/ MB[\+?&GXFEX6;^..S\2>(/$>DN0>=KV[+[$<5T87Z2WBUAYJ5;&X7$)=*F#P MNO\ V]"E3G]TK^:W>53Z.'A*Z$L/A\!B*,97^#&8MVOVYZTTM]K6_3\Y_CC_ M ,&YU[:6-UJ'[-/[1%W=W,-O.8/!WQJTBVM/MS(H:&WB^('P[LM/BL6D"E"] MWX>O,ZT:?&.40]FY*]7!R;Y>[]AB)3YN]H8BE_E^0\1_1# MPT<+;@W-Z].K&ERJ&)LN>2M9NMAHTDFTFFYT*VK3MHT_Q \<_";]MS_@G!\2 M+:XU73_B?^SWXIN;Z.'1?&7@K6I],\+>-3:37301Z1XL\+SS>!O'PEBB=SIN MI)/>B%BT]A&I('])Y;GOAGXQ9.X4IX/-<)&#9RI5?W^'LVDZM M&4:?,K1K29_,V:9%XN^">;^W2Q>";G",:E&7+3K1A4J.G"-2FGAZ[DE)^RJP ME6Y9ZX>-]/V>_8B_X.!-;LKO2O 7[;.D1:SHS+':Q_'7P/H?V;7=*$<,2"Z^ M(7P\T>)K;7K5GW//J/AZ&"XC')THH&E'\\^)7T5*+A4S3PXJ.%>]_J5:=X2N MWI0Q$VG!I64:>((T4E"FV\92@^9MZ5>()+:_TS4K*6:VN[:53PRMP<@@$$#^)\PR_'95C:N6YE2J4, M?0FX5*=2+A.$XNSC*,DG%KJF?V]@\9A,QPE/'8"K3K8*M!3A4A)2A.,E=2C) M-IIK5--_Y]*>A^AKC.D_AQ_X* 65EJ'_ 6P\266HVT5Y87?[1?[(UG?VLT: MR176GWVG?L^6.HVLD; K)'=V%S+$P((*N:_TG\+JE2E]&VC4I2<:DGBH*=+^T\J=G_U[RU?DW\CVK]@*6?]B#_@ MLMXZ^ 5\\FF^%_&'C?XM? B"!+ATM)M%\33+\6_@??RVLACB+KH]EI]G&0"5 MGU.15)#'/S7BFH^)'T><)Q53]_&X;#83&-M>]ST_]CQJ4E=ZU'.HU=7C23>J M5OM/"ZE#PY^D+C^%E!4(_A[^R5X7^#EGJ"VFK_'WXA:=9ZK$+MH9E^'GPU6+QUXKN&MX@ M9[BRN=;M-'T^=6;\>5L_G!RP^5824HZ73Q&(_<45=Z M*2C*K5B][T[K:Z_7OI0<4TLEX"IY$IPCB'H+V]>48P3G47NTZ M4XJT6JMI/7EG_-_^V?\ F7X"_ #]A/1]6TO^SO&'Q"_9N^*WQG\9":T^R7R MZI\3_'UCXCT?2[^-V:<3^&?"=S8Z>%%_"^AVT6I>,?'/B(_#S2+U/#_A72);FTBN;I+*VDGN+B MXFMK&QMD::YGBB4L/\_4HPBDY3E&*;7Y*W7_!Q#XBN'U+Q3X>_8@\5ZA\*-&U6'3M3\7WOQ(U M2-[+<]NLD>J:KHOPIUSX=Z-JH^TKBUGUT89E4N-P)_>:?T3\)%4\#C.)SLM-?P"K]*C%SA7S3 <-8JKPUA\1"E/ M$.O)63<.:3<,+4PT''G^&6*6R4I0OI^PG[$W_!03X%_MV^#]=U7X9S:QX;\: M>$HX/^$X^%WC%=/M_&'AN&^:Y@T_6(6TN\O](\0^&-2N+2:.#4+&>6)9HG@G M6"X5XE_ /$;PMXF\,\PI8?.E3JX"O?V.)I.3HU&DG*'O1C.%2*E%RIU(J5FI MQYH2C)_OGA_XE\-^)&63QV1RG#$4I.-6A5Y55IVE**D^24X2A)Q?+*,Y+1QE MRSC*$?Y;?^"*W_*3K0O^Q;_:1_\ :-?VG](K_DRJ_P"OV7?^D3/XX^CQ_P G MIQOIF?\ Z?IG[H?MH?\ !:SX/_LS?$G4_@?\+_ASXB_:&^+N@ZM#X=\2:?H. MK)X>\(>'_%%P;7;X2_MN#2/$NO>*?%EL+E5N;+1M*O5M9C]GEE2Y5X5_FSP\ M^CKQ!QED\.)'ZM-U*>K.DN:]7DK3YE[\4X6;_ M *'\0?I"\.\&YM/AK*,+7S;B6%>%&5*FW3IQJU.2U/VG).=2:4XN4[U6 M.!M,E^(.E^)?"OP_\;^#M)N6N$5K]M,N;2W219[AH;8/,GT'$OT6\YPF3RSK M@O,\/G5"-*4U3C!0JU%!M36'E2JXBA6DK-\BK1G*SA!2J6B_GN'OI09'6SU\ M/<;9=7R3&+$1I.I.HIT:7/352$\1[6&&K482;C#G="4$YPE*2@W./ZP_M>_M MD?!O]BWX3O\ %;XL:C>W$.H7G]C>"_"/AQ+.\\5^/?$YN[ZZG@L;&T1I9I5&T-^&(>>K(\BA%3C'GJU:EU2HT[J+G4 M:C*7Q-1C",93G-J,(ML_=>-.-\AX#R26>Y]4<<.G:$8V+-)^%>MZEJ-CH_BK2_B2;K5+] M=-F>*\739/$'P^\+_#_7-4T]8V-U:VNOL;9P5D==K,/Z1K?1-C*E/"X#B+#5 M,_I0A*=&6'M&/,DUS>SKU<1",KKDG/#+G5FD[I/^<Q5#AJO M5J0IXA5U)M4Y-7]^C2PTG9-SC#%3<+23ORS /BC\0W^&MMI&BWFC^$_$_A7Q):>'?%6O:QIWBVQ\42P1Z7JFA/ MX5EMKFVW%R\LQFI*33O:U[J_U+^Q3^UAHO[:/P&TGX[Z!X+USP#INK^)?&GAJ M/PYXAU/2=6U2WF\%>(KWPY=74MYHC2:E1HU'4IQG:E&JDE-1E>*DD[Q6NVEF_M>".+<)QQPY1XD MP5*I1P]:52*A-IRBZ&OVSIOV,9O@ M5X^N_$2?&_PW\$!XZ@\5^"XO#S:CXDN/#\,7B :7<72:Y_9UE%X@1Y8O*,Q\ MIE0,2N?TG ^ &;8WP[7B+',L)'!?V=5Q?L73K.IRTG43AS*#AS2=-I/FMJFV ME>WYWF7CGD>6F_#R]O_B+< M:)\'[N;5HO&5A#%HUM!%MSO9T6)%V87A?YU\-?";CGBW@RGQ M%DG$,LORQ3KQ5#GQ:Y71]Z;2I>XN:]^C;;W>I_17B+XK\$<(<6/A_.LF>-S6 MI"@_:*&'?-[9\E.+=5J3]Y./512O)QC9OUK]LW_@L=\/?V+?CK=_ ;Q!\#/' M'C2^L?"7@CQ0OB/0/%G@K1-&%KXS75%M+$VNNW-M=PR::-(?S7P8MA# \$#Q M/#SP SGQ%X:7$V"S'"X>E+$5J7LZE.O.=Z*@Y2O3A)-2YU9;WTMJK^IXB>.W M#_AOG<M?C+XJU_5_AQX3\;:E8EDU"W^'TR> /% M5AJODR6MPL2WEY974ODEOLZQ_-7V?#/T5\=F6%Y.(,YPV!X@=)5'@Z<(8BM1 MC+X7B%[>G*G?FBVX0J12E;FYM'\+Q9]*3+LDJ1Q619/BL?PVZKI+&SE.A1K5 M(\W-#"R]A5C6:Y)_%.E=QM'F5VOU3_8;_;V^#7[>/P_UGQ;\-(]9\.>)O!U[ M8Z9\0/ASXI^P'Q)X3NM5AGN-&O?M6E75[I.N>'->AM)S8ZA:RF.5[>:&1(;F M":"/\2\2?##B+PQS6G@,Z]G5PF(BY4,12YO9U5%I3C:<8SA4IMI5*#QU"M*,E=2C M3J1E)-=4XIIG@\4Y0\_X:S#(XSE3EC,%6HJ2M>+J4Y04E>ZNFTU=-::I['^? M-\.?VU/VP/@7JJ2> _V@?C;X+O;)1!>Z!<^.?$.NZ1;7T+*M_IU_X.^(,WBS MPP)M-U""2WD1K ,CQLI(.0/]6,U\,_#SB?#6S'*LLQ%*3O&I&C3IR<7\,HUL M-[&HU*+4D_:---.VQ_DUA_&+Q,X/S9T\-F>8PE2@X.$ZM64>9VYN:EB_;QYJ M> =-\8Z'--#;2?%#X5Z:GA_Q= MIL._HFX&=*>.X"Q4Z M&(2;^K8J7/2E:[M#$1BI4V]$E5A."U&@U*48JOA MX\DU?D5YT)3E&HN9S;=*HJEK1AAIM7?]/?P8^.'PH_:&\ :+\4/@SXYT+X@> M!]>1_L6MZ%A-6T>THM7C.$EK&<&X25G%M-']IY!Q!DO%&54<\R#$ MT\5E=>"E"I!Z-/HT[2C);2A)1E%W4HIII=!\0_AQX"^+/A#6_ 'Q,\'^'?'? M@KQ':266M^&/%.DVFLZ-J-NZD?O[*]CDC$T1.Z*5-LL+@.C*P!'+E6;9GD>/ MIYID]>MALQHRYH5*4W"<6NJDK/U6J:T::T?7F&78#-L'4R[-*-+$8&K&TZ=2 M*G"2[.+NG_7R_CK_ ."H_P#P1SUC]E^RU?X]?LZC7/%WP"M6EO\ Q=X6O\ H#X)?2$H\8U: M?"W%_LJ'$TK1I5(I0I8M_P JBK1I8A]*<4J=?:E&G5Y:=7_/CQW^C8^',-/B M[@=5:F4TVY5J;;G4P\=^;F=YU*,?^?DFZE%:U'.DN>C\W_\ !,G_ (*:>._V M'_']OX4\776L>)_V=/%6L9\>^!T\V^N_"][>2A+SXA^ +,Y-MXELS^]U+3HM ML6OP*WR_V@(I)?K_ !H\%\L\1\K>999&G1XLHT_W-71*K%+2A7>EZ;VI5'K0 M=DW["ZA\?X#^/&9\!YK'AWB.)_"/BW1=.\1>&O$6C74=[I6MZ'J]I%>Z9J> MGW43-'/:WEI,KHP/0\X.17^9..P.,RS&U,PF8X2EC\!4A6P5:G&=.<&I0G"24HRC):.,DTTUNF?Q/?MY M_P#*;K7/^SD_V/?_ $1^SK7^C/AE_P HU4_^Q-F__O1/\Z..O^4K,1_V,LJ_ M](RP^H?^"\W@#6/@9^UQ\ /VOO!UHT-WXATG1-0-RD6V'_A9_P"SIXHL/%GA MY)+F-=T-UXC\-:A!"222T&EL!D*0?B/HPYG0XFX$S;P_Q\O9?WJOFF?H7TF,MGPYQMDOB%A81IX89=7\'_!C..*LQ@Z> M)K*ZU4J,G@L"FI62_P!IE.IK=N$D[/KP>*&/H>+'C/D_!F JJIE$(X>$TJOL MTXU8K&XQPG!.I*2PL*<$HN"YKIR6LETO_!QK:VUC\:OV=[&SACMK.S_9X^(% MI:6T*".*WM;?Q?ID-M!$@X2.&%%4#L!7']$6U;Q!J:HV4>2Z;X>:3"QQ]VTVG(.*^V^CIE6#H97G68QC_M M6,XFQ-.I+^Y0E2A"/R^M5GZR\CX[Z2V.Q>+S_(\IJ3_V"CDU&<8V5U.JJU24 M[N_7!T$E:WNR33OI_8U^SW\'OAUX)_9?^%7P'Y[2 M*ZTS6[#4_#-DFN2ZQ;S!X]4N/$4UY//>R3!WN9IW=RS,37^?_%&?YMFO%^-X MAQ5:I_:U3&U*OM$[2C)5&X\C5N50LE!1LHI)+1)']Y\.Y%E>4\,83A_!481R MJC@Z=)4VKIPY$FI7OS.6KDW=R;;;;=W_ !U?\$R;^\^"O_!6CP;X"\$W-Q'X M:NOBO^T#\"[ZT6:2==1\!6$/Q1BL+>ZED)FN/L=Q\,-%NA([,S26F\Y8DU_? M_C+3AQ)X#5LVS-)XY8'+\:GHK5Y?5>9I+176+KQLE9*5DDDD?P1X.TO]5_I MRR3*).&5_6,9AG#XN:DOK2BN:5Y>[]2P[3O=\CYKMMO)_P""4/B.]\)_MW:_ MXNT]=^H>&OA)^UUXBLH]H827FC^'+S5+9-IR#NN+5>.KC5@_S7]=?GK]@#]HSXF?!' M]I2/XY>$?@7??M/_ !,'@7Q7?KH9M/&FK:O8:SX\G\.ZAXI^)"/X'\'^.->C MU"*YO+N!YS9K"O\ ;#7*H-1Y^9^PBU&2BVO@O"/C+.\E\2<3G>'RNIG6:_5*LE[M6= M6$J[H3JU5*E1KU%[TIIV@HKV\ES1NHR^D/V_OBE^T]^WSXV^'7C;Q+^PE\3O MA;K7@OPYK?@_5+_PW\+OCUXFN_%N@ZSJVE:E:0:O=ZK\'_#L\*^'1:WL=J@\ MX%-4N/F0'!^.\*\FX+\+,NQN7X/BC XZAB:L*L(U,3@*4:52$)Q;C&.-JI^T MYH.3]W6E#>VGW7B]B^-O%''Y?C7PSC,%6PL)TZE2.'QU2K.E.=.7*I_4Z>?\%*?B=\5_%'AC]A;PK\3HO$NF:Y\/?V OAIJEYI'B[3M6 MT;Q+;^-_$E_XVL_$^HZUI>MPV>J6&LW"?";1TF6>&.<-$=WWC7K^#.2Y%@L9 MQ/C\E=&>%Q?%>)A&5*49TG0I>Q=*,)0O&4+8RJXN,G%IJW=>1X[YCG>*_P!5 M\ESN4XU%X'QD:D\_P TYWDI5))-_\ DUF!_P"PC%_^I58_G^^+'_*=1_\ L_;X9_\ H_X<5_4G#^GT87_V3.)_ M]+Q)_*O%G_*4N$_[*##_ /IC#%?]L#_E-OKG_9Y7[-'_ *,_9JK7@#_E&R'_ M &3V9?\ O3-/$'_E)JC_ -C? ?GE1>_X+6_\I.O%/_8O_LY_^DBUG]'+_DR\ M/^OV8_\ I,1?2-_Y//AO\&6_^GIE'_@O)G_AOKQ,58HW_"E/@K&CKP\;36GC MN$31L.4FA\S>C#E7 /:M_HMZ^&-*+V_M/&7\[?5G;T>S\F_EYWTMZSP_'L,1 M%1BV?@GP/ M^ROXT?PEX>MM/MHM.\/W'@/P#Z%JVD6]S!,BK(D\8<$-D MU_%GAMG>:UO&/)\VK5ZLLQQ.>T/:U')N53V]>,:JD[WDJD9RC)/1IM-6/[0\ M3LJRS#>#F=Y;1P]%9=APP\IT>6%N5>SE"+C:W*XIK5*_X8?\ M&X-S,WQD_:@B#E(;GX4?"V[D@3Y(#,GC[X@>6PB&5'E+=2*G]U6([U_2WTO8 M)9+DG64<;BTF][>PPOYV5_0_G#Z'-1U%F]1V3G0P\FEHKNOC'HNRNTNR/ZW: M_A,_N(__U/[^",_Y_7GN* /XB_\ @MG^P;K/[/7QZU7X]^"-"D;X)_'GQ#>: MZMQ8Q;K3P7\6-6,VH^+_ A>I#$L=A:>+[Y9M* MR?/I<:9/2OD^.J;O[U- MZ7@W_%H2?LZJ_DJTADECMM9T:Y<#$UKJE*,E*$U&<9)?ZR<%\8Y)QYP]0XDR&,E:<'*$HR?T+=VEK?6MQ97MM!>6=W!+:W5I M=0QW%M)_T; M<;7\3,#7X1H^SR',JU^:$;QP?!GP#9O9>#_ (:^$=&\(:#%*Q>ZFM-'LX[=K^^E8LT^I:I=6HUHN:3 82A"E35[OEA%15V]6W:[;U;;;U9_([^V_\ [XUZY_P M6/UGQWH?P;^+VN>"9/VB/V3M0C\8:)\*_B'K'A)]-T>W^ AUG4U\5:9X8NO# M?]FZ.=*N1=SF[$5J;>7S67RWQ_=WASQ/PUAOH]4\IQ.8Y?2S-91FL72GBL/" MKS3>/Y(>RE557GGSPY(J%Y5.ZO_#/&?!G%>)^DG6X@P^78V>3RS'+6JT: M%:5)QIT\O=2?M53=)1A[*HI-S34H.-KM)_N1_P %H_V<]5_:#_8A\5R^$_#> MJ^*?'WP@\4^'OBMX3T7P_IVJ:MXBU6WTVXN/#OC72-%TK1K:\U'5K_4/ GB/ M4/)M8HI'GGBC"J6VX_FWZ//%U'A/Q)P[QU:%#*L?1GA:LZCC&G'G2G1G.4W& M,(QQ%.DY3!HO'?@?Q+X&DU+Q+\1]1>;Q)J6D6?BS1-%U#4%T+POX5A@:>!#"&UB1"Y?< M!^X?2C\0\GS'AK \-9!C,+BOK6*=:LZ%:G7Y:>'C:E&_#KX4_%'XA6=A\"_'^GWUYX!^&_CGQO M9V.H7?C"QFM+"^N_"?A[6K>QO;J&-GCBF9'=5) (&1S?13S_ "#)LAS.&<8_ M X.I/,L-**KXBA0S:74]CZ47#7$.?YEE$+GQ#\6OAA^S_X!^'?Q#^&30II7BOQ5X''AG3-0MCHEIJDNFFX\5^! M]8NK^.72IY+>>YLM1N5A;[7##!-X7@MXOY-P=Q3G'#G$>(5'(<;F56O0Q&LZ M5*NIRB^?EYK4JT%"U2*DHSITW)>SE*-^'\KXBX:H*IQ)@L)3HU M*3]RK5H-1=H.4H+GHR<_WO!?A&T\!>%?'^N:!\3-(CF71M/_ +'\/:SXQ^&$GPY_X2/5/$FF M6EM!]I@L[J*WU2=/,\RT$A2/ZC.OH]\ 9]Q15XHP7$.%H\*XC$.M4H0JX64E MSRYJD*.(^L.E&G)N7+*<7*E'1QJN*O$G)N&J/#&8<-8ROQE2PWLZ> M(='%1H.48RC3G7HNA[;G24/:0@^6I)MJ=)-J'H__ 1E_P""//$GC+Q];74?B7XG>(/#\V+SPK8P:5J MM_!96][%;ZA=7>JW,KV]O##;F?R_I"^+W#>-X?CX=\&5J>(HRJ4_K%2B^:A3 MI4&O98:G/:J^:-.4Y0(:OB1QS2=+,)0FZ$*L M6JTJM?WJN(E%R;I1M.I&%.I"-7FJUKQIPY(/Y._X)(?L_?%S1/\ @H597WQ$ M^"GQ=\+>"-2\'_M&Z5?ZWXN^%?Q"\*^')+;Q'9FVM;237O$/AC3-'$FK6DCB M!//W3#[H)&!]IX\<5\/XSPFCA\JS++Z^9T\1E\E"EBL/5J)TXOF?LZ=24[0E M;F?+HSYOP+X1XCR[Q7Q>89KEV.P^6589A:=7#UJ4&JM6+IKFJ0C%\\$Y))NR MTERR:3XWPG\,OVK?^",?[9-[\0[?X'>*_BW\++"Q\8^!=&\2:3IGB.]\,?$G MX1^(+G1;K2 OC'PIX>U^V\%>/=(C\.:4US:ZI:1!;ZTG6-9K6>.[7U,PSS@; MZ0WA[#*JN:8?+\]E.C7G3G*G&=#%P513_=5JD'6H3=6KRRI3D^2<'+EJ0E2E M\]E?#WB!]'[Q#KYSA\KKYKP\X5J:J0C.I*OAI>S=.U2A1Y:->/L:*G"K3A#G MA/EE.%15*?TSXS_X*"_\%1OV]?B[X3\-_L6?#3XI?LZ>%HK&31Y3#H5IK&AB M_P!4OK?[3XY^*GQ*^(7PL_X1?2-%\.P1*8+#2R;PP&?8M]<30PP?&9=X6>"7 MAED-?&>(N.P.<8YS4[*I*,^6*=J&%P^'Q2JRG4=TZE9*FI+\3 M_&[Q&SVAA> ,LQ63Y2X\O-6I6:G>5ZN)JU\-*BJ*CRN-.A>MI*SFYGPV$&I^)=)\21WL\^F6B)+/8ZO<_8XFG@AMI?B?H]>+>1\,9SF'#N M=2AE^0YEBO;X:3+ MLAP>?Y-&6-XARO#2IUHJ*]OBJ-E*7L^3D3J<\7[D4KPJU/914^2+_-+Q[_P4 M7_; ^+/['7@#]A;PU^SS\7M&^)/AO3O ?@KQ5\2O"^D?%Y/'GB?P[\-[O2I_ M#VG:1X4\/>"M*\2^%?$&N'0[6#69Y+YD:%94B3;M2PU2>#=&G/$*2FYU:E>=*K3I\\I44H-\W*Y-."4_P JSKQ6 M\4,VX"H^'^79'F5+B'#0HTZV*A3QO/5AA^22]E"E0A5A4JN'+6O.RBY*'/SM MP^NM=_X)9_M5>)?^"5NH^%_%MQXJ\7_M,WGQVT?]I2#X:>)O'-_XH\0:7X7T MKP7>?#=?AG8:MXB\0:QI<7C*?P5JEUJ\EA'?K9'6)VM%GW?OC\%@_&O@C+_& MZ&89;##X;@R.62R]XBE0C2A.I*JL1]9E"G3C)TE7C"DING[3V$5-PO[A^@9O MX+<8Y]X*O(TR[^&^HO/X6O\ 78'O6N9C:26+/!GPR^(NN?#2VO M_$/B_P +^(-4NM#\:6'AFY\*R^%/"UAK,5D]RE]);6<6G21R3N8'F?ZC'<4^ M'5;P5Q64<+YC@X8+^P<31P]*OB<-#$M4Z=6$8SHNJJOM:LH2FH\BE-U8N,8J M2@OE<)P3XIT_'+ \0\68&K5K?VSAZ]:KAJ.(J89<\H\TH573E3C3I1<8-2J) MPC1=^;2I4]F_:O\ @=\;-8_X+':YXYTCX,?&'5?!1_:Z_9TUA/&.E_"?XBZG MX1DT?3I/V?3J>LQ^++#PQ<>&FTC2QH]U]JNOM?D6WV>7S&7RWV_.<#<3\-X? MZ/<,KQ&8Y=3S+^P2'LI555YY\\.2/)S2YH\J?,C[+CGA M'BC%_2&I9UA,/#)T#X!*GB/PA\*?B)XK\/ROI5FC:I'%K MGAWPUJFDR2Z:K#ST$VZ+HP!XK/P XFX;RWPCA@,RS'+\-C76Q_[NMBL/2J>^ MDH/DJ58SM)JT7RV?Y9^/W"G$^:>*U+-I MTYJ\(M2:O=[14I7BJW_!;3X&?&WX@_MS>(M<\"?!KXO>--!?X/\ P9M(]>\' M_"GXC>+="EO;"'QC]NL8]:\,^&-8TMKZR%S%YT/FB2(2+N R,[?1MXHX:R?P MXIX;-!PZYZ6'KU8&DN6_-H])6_J*_;0T76-?_8>_ M:?\ #^AZ3JFLZ[K'[,WQ9TG2=$TC3;[5=9U/5+[X;ZQ:6>FZ;I.G6]UJ6H:C M=W4BQQ6\,4DTLC!45F(!_BWPYQ.'PGB3DF,Q52%/"T\YPDYSG*,(1C'$0^ M._ASXX\$66IWEKXW\97-U::9=^+O#^B0ZC))%+ !A7]._2JX M@R'.\FRB.3X[!8NI#&XJ4HT,10KN*='#J+DJ-2IRIM22,E^C3LXR5G& M24DTTFOY!/VW/^"$'QT^$^LZQXS_ &7(=0^._P +Y[F>\@\))/8P_&7PE:-\ MXL;K3[N73]*^)%I;%@J7MA+;:I(@ ELKF;?-*3V:=D[-:]+_J MM_P1P_;"_$7B:S/P=^/.JZ%\//&VDKK=C=6ND>)]0NAIGP M[^(-M8VTUQ,+W2-:NX]*OW0 2:1?EY24T^$+^$_2'\-Z7&W!E;-<%0FN(,KI MSQ%*?LY1U6FXQ]ZO)O\ I7Z-/'N;<%\4TLBSFI;A M[,)PH.+J0E&-63Y:%51CS3YHRY:$M5'V,XRE:.'1_>&#FO\ ,8_TS# _S_GG M% !0 FT$YY_[Z('Y!A_*G=@& >/YISDXS M1?^^CC\MP'Z4[L!-H]_P9@/RW#^5%W_ M %8!2 3GG\&('Y!A_*BX 5!]?P8C] R_Y_4NP%_S_GI2 0 #U_$D_P V;'^? MP=V M(#_UO[^* "@ QGK]: ,#7?"OAGQ1 +;Q+X>T/Q#;*"!;ZYI&G:Q" &KD7?AWP%X+T"ZSG[3HOA30-*N,CH?/L+""7/X__ %MZ^:9EBH>S MQ.(KU(=I5)R7W.37]?=G2P6#HRYJ-*G"7>,8I_@E_7X]O7 =(4 % !0 4 % B!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$! end XML 9 mbrx20211106_8k_htm.xml IDEA: XBRL DOCUMENT 0001659617 2021-11-12 2021-11-12 false 0001659617 8-K 2021-11-12 MOLECULIN BIOTECH, INC. DE 001-37758 47-4671997 5300 Memorial Drive Suite 950 Houston TX 77007 713 300-5160 false false false false true true Common Stock MBRX NASDAQ XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Nov. 12, 2021
Document Information [Line Items]  
Entity, Registrant Name MOLECULIN BIOTECH, INC.
Document, Type 8-K
Document, Period End Date Nov. 12, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37758
Entity, Tax Identification Number 47-4671997
Entity, Address, Address Line One 5300 Memorial Drive
Entity, Address, Address Line Two Suite 950
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77007
City Area Code 713
Local Phone Number 300-5160
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period true
Title of 12(b) Security Common Stock
Trading Symbol MBRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0001659617
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mbrx.com/20211112/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mbrx20211106_8k.htm ex_303877.htm mbrx-20211112.xsd mbrx-20211112_def.xml mbrx-20211112_lab.xml mbrx-20211112_pre.xml moleculinlogoresizedclear.jpg http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mbrx20211106_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "mbrx-20211112_def.xml" ] }, "inline": { "local": [ "mbrx20211106_8k.htm" ] }, "labelLink": { "local": [ "mbrx-20211112_lab.xml" ] }, "presentationLink": { "local": [ "mbrx-20211112_pre.xml" ] }, "schema": { "local": [ "mbrx-20211112.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 28, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mbrx", "nsuri": "http://www.mbrx.com/20211112", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20211106_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.mbrx.com/20211112/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20211106_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity, Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.mbrx.com/20211112/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001437749-21-026281-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-026281-xbrl.zip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